Table 3.
Antibiotic selection, duration of therapy, and clinical outcomes.
| Total cases n = 100 | |
|---|---|
| Antibiotic selectiona | |
| Oral β-lactam | 73 |
| Cephalexin | 65 |
| Amoxicillin/clavulanate | 5 |
| Other oral β-lactam | 4 |
| Oral anti-MRSA antibiotic | 28 |
| Doxycycline or tetracyclineb | 17 |
| Trimethroprim-sulfamethoxazole | 7 |
| Clindamycin | 5 |
| Fluoroquinolonec | 10 |
| Intravenous antibiotic | 5 |
| Vancomycin | 2 |
| Ertapenem | 2 |
| Ceftriaxone or cefazolin | 2 |
| Antibiotic with broad Gram-negative activityd | 18 |
| Multiple antibiotics prescribed | 18 |
| Sequential therapy | 12 |
| Combination therapy | 6 |
| Treatment duration | |
| Total duration of therapy, median days (IQR) | 7 (7–10) |
| Duration of therapy ≥10 days | 43 |
| Duration of therapy ≤5 days | 6 |
| Clinical outcomes | |
| Treatment failure | 15 |
| Required hospitalization | 4 |
| Discharged to home with antibiotics | 3 |
aTotals for subgroups include 18 patients who received more than 1 antibiotic.
bIncludes doxycycline use in 16 cases and tetracycline in 1 case.
cIncludes levofloxacin use in nine cases and moxifloxacin in one case.
dDefined as β-lactam/β-lactamase inhibitor combinations, second- or third-generation cephalosporins, carbapenems, and fluoroquinolones.